...
首页> 外文期刊>Neuromuscular disorders: NMD >Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy
【24h】

Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy

机译:在怀孕期间,酶替代治疗alglucosidase Alfa在怀孕期间患者

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical data regarding the use of enzyme replacement therapy (ERT) during pregnancy in late-onset Pompe disease (LOPD) is still scarce. We present the clinical case of a 32-year-old female patient with LOPD, on enzyme replacement therapy (ERT) since the age of 29 years old, who had treatment interrupted after her second week of pregnancy with subsequent deterioration of her muscle condition. ERT was resumed by week 20 with clear clinical improvement. The pregnancy and delivery was otherwise uneventful and there were no problems during the neonatal period. After one-year follow-up the mother was clinically stable and the child had a normal development. A review of the existing literature shows that maintaining ERT during pregnancy may be of crucial importance for LOPD patients without adding obvious risks to the foetus. However, more data needs to be collected to address safety for the foetus and exclude potential teratogenicity.
机译:关于妊娠期妊娠期妊娠(LOPD)在怀孕期间使用酶替代疗法(ERT)的临床资料仍然稀缺。 我们向32岁女性患者提供了卢博德的临床案例,酶替代治疗(ERT)以来,自29岁以来,他在怀孕的第二周后治疗后,随后对她的肌肉状况恶化。 第20周恢复了近期临床改善。 怀孕和交付是不平衡的,新生儿期间没有问题。 一年后的随访后,母亲在临床上稳定,孩子的发展正常。 对现有文献的综述表明,在怀孕期间维持偏移可能对洛佩德患者至关重要,而不会为胎儿增加明显风险。 然而,需要收集更多的数据以解决胎儿的安全性,并排除潜在的致畸性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号